Schisanlignone C exhibits significant anti-inflammatory and neuroprotective properties, making it a compound of interest in the development of treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. It has been shown to inhibit key inflammatory pathways in brain cells, reducing the production of pro-inflammatory cytokines and oxidative stress markers. Additionally, Schisanlignone C demonstrates hepatoprotective effects, supporting liver function by protecting against toxin-induced damage and enhancing detoxification processes. Its ability to modulate cellular signaling pathways also suggests potential in managing metabolic disorders, such as diabetes, and supporting overall cellular health, including applications in chronic inflammatory conditions like arthritis. Research is ongoing to explore its bioavailability and therapeutic efficacy in preclinical models.